Lupin gets USFDA nod for contraceptive pills

Lupin has launched nine products in the US this fiscal and received approvals for 21 from the USFDA

Bs_logoLupin's Goa facility
Lupin's Goa facility
BS Reporter Mumbai
Last Updated : Jan 09 2016 | 12:05 AM IST
Lupin has secured US Food and Drug Administration’s (FDA) approval to sell the generic version of oral contraceptive Generess tablets in the American market. The tablets have an annual sale of around $90 million and Lupin will benefit as there is only one more company distributing generic version of the drug in the US. Lupin’s stock closed flat at Rs 1,712 on the BSE on Friday.  The approval is important for Lupin, which has a large oral contraceptive business in the US.

Earlier this week, the drug maker launched generic version of Ortho Tri Cyclen Lo tablets which have sales of $ 488 million in the US.

The Ortho Tri Cyclen Lo  represents Lupin’s 16th oral contraceptive launch in the US. The company has filed 37 oral contraceptive products with the FDA till date, Lupin said.

Lupin has launched 9 products in the US this fiscal and received approvals for 21 from the US FDA.

You’ve hit your limit of 5 free articles this month.
Subscribe now for unlimited access.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 09 2016 | 12:02 AM IST